Cantitate/Preț
Produs
Total produse
Vezi coșul
Handbook of Anticancer Pharmacokinetics and Pharmacodynamics de Michelle A. Rudek

Handbook of Anticancer Pharmacokinetics and Pharmacodynamics: Cancer Drug Discovery and Development

Editat de Michelle A. Rudek, Cindy H. Chau, William D. Figg, Howard L. McLeod
en Limba Engleză Paperback – 23 aug 2016
There are many steps on the road from discovery of an anticancer drug to securing its final approval by the Food and Drug Administration. In this thoroughly updated and expanded second edition of the Handbook of Anticancer Pharmacokinetics and Pharmacodynamics, leading investigators synthesize an invaluable overview of the experimental and clinical processes of anticancer drug development, creating a single indispensable reference that covers all the steps from the identification of cancer-specific molecular targets to screening techniques and the development and validation of bioanalytical methods to clinical trial design and all phases of clinical trials. The authors have included new material on phase 0 trials in oncology, organ dysfunction trials, drug formulations and their impact on anticancer drug PK/PD including strategies to improve drug delivery, pharmacogenomics and cancer therapy, high throughput platforms in drug metabolism and transport pharmacogenetics, imaging in drug development and nanotechnology in cancer.
Authoritative and up-to-date, Handbook of Anticancer Pharmacokinetics and Pharmacodynamics, 2nd Edition provides in one comprehensive and highly practical volume a detailed step-by-step guide to the successful design and approval of anticancer drugs.
  • Road map to anticancer drug development from discovery to NDA submission
  • Discussion of molecular targets and preclinical screening
  • Development and validation of bioanalytical methods
  • Chapters on clinical trial design and phase 0, I, II, III clinical trials
  • Pharmacokinetics, pharmacodynamics, pharmacogenomics, and pharmacogenetics of anticancer agents
  • Review of the drug development process from both laboratory and clinical perspectives
  • New technological advances in imaging, high throughput platforms, and nanotechnology in anticancer drug development
Citește tot Restrânge

Toate formatele și edițiile

Toate formatele și edițiile Preț Express
Paperback (1) 173259 lei  6-8 săpt.
  Springer – 23 aug 2016 173259 lei  6-8 săpt.
Hardback (1) 176152 lei  6-8 săpt.
  Springer – 11 ian 2014 176152 lei  6-8 săpt.

Din seria Cancer Drug Discovery and Development

  • 5% CNS Cancer: Models, Markers, Prognostic Factors, Targets, and Therapeutic Approaches
    Preț: 139689 lei
  • 5% Developments in T Cell Based Cancer Immunotherapies
    Preț: 104973 lei
  • 5% mTOR Pathway and mTOR Inhibitors in Cancer Therapy
    Preț: 134080 lei
  • 5% Antiangiogenic Agents in Cancer Therapy
    Preț: 137019 lei
  • 5% Tumor Models in Cancer Research
    Preț: 137541 lei
  • 5% Telomeres and Telomerase in Cancer
    Preț: 131674 lei
  • 5% Gene Therapy for Cancer
    Preț: 136330 lei
  • 5% Proteasome Inhibitors in Cancer Therapy
    Preț: 105400 lei
  • 5% Oncogene-Directed Therapies
    Preț: 106668 lei
  • 24% Protein Tyrosine Kinases: From Inhibitors to Useful Drugs
    Preț: 103759 lei
  • 5% Cancer Chemoprevention: Volume 2: Strategies for Cancer Chemoprevention
    Preț: 138872 lei
  • 5% Apoptosis, Senescence and Cancer
    Preț: 135078 lei
  • 5% Bioinformatics in Cancer and Cancer Therapy
    Preț: 134252 lei
  • 5% Bone Metastasis
    Preț: 105458 lei
  • 5% Nitric Oxide (NO) and Cancer: Prognosis, Prevention, and Therapy
    Preț: 135293 lei
  • 5% Tumor Suppressor Genes in Human Cancer
    Preț: 135411 lei
  • 5% Platinum-Based Drugs in Cancer Therapy
    Preț: 74082 lei
  • 5% Regional Cancer Therapy
    Preț: 136243 lei
  • 5% Checkpoint Controls and Targets in Cancer Therapy
    Preț: 105088 lei
  • 5% Antifolate Drugs in Cancer Therapy
    Preț: 135847 lei
  • 5% Transforming Growth Factor-Beta in Cancer Therapy, Volume II: Cancer Treatment and Therapy
    Preț: 136582 lei
  • 5% Transforming Growth Factor-Beta in Cancer Therapy, Volume I: Basic and Clinical Biology
    Preț: 138372 lei
  • 5% Farnesyltransferase Inhibitors in Cancer Therapy
    Preț: 104832 lei
  • 5% Supportive Care in Cancer Therapy
    Preț: 98218 lei
  • 5% Nucleic Acid Therapeutics in Cancer
    Preț: 68941 lei
  • 5% Stem Cells and Cancer
    Preț: 133176 lei
  • 5% EGFR Signaling Networks in Cancer Therapy
    Preț: 129740 lei
  • 5% Hematopoietic Growth Factors in Oncology: Basic Science and Clinical Therapeutics
    Preț: 106512 lei
  • 5% Sensitization of Cancer Cells for Chemo/Immuno/Radio-therapy
    Preț: 135723 lei
  • 5% Hormone Therapy in Breast and Prostate Cancer
    Preț: 105213 lei
  • 5% Platinum and Other Heavy Metal Compounds in Cancer Chemotherapy: Molecular Mechanisms and Clinical Applications
    Preț: 131776 lei
  • 5% The Oncogenomics Handbook
    Preț: 138735 lei
  • 5% Macromolecular Anticancer Therapeutics
    Preț: 183685 lei
  • 5% Histone Deacetylases: Transcriptional Regulation and Other Cellular Functions
    Preț: 134338 lei
  • 5% Cancer Drug Resistance
    Preț: 136277 lei
  • 5% Matrix Metalloproteinase Inhibitors in Cancer Therapy
    Preț: 104210 lei
  • 5% Fluoropyrimidines in Cancer Therapy
    Preț: 105126 lei
  • 5% In Vivo Imaging of Cancer Therapy
    Preț: 99058 lei
  • 5% The Tumor Microenvironment
    Preț: 136674 lei
  • 5% Camptothecins in Cancer Therapy
    Preț: 135327 lei
  • 5% Targets for Cancer Chemotherapy: Transcription Factors and Other Nuclear Proteins
    Preț: 74600 lei
  • 5% Cancer Proteomics: From Bench to Bedside
    Preț: 131172 lei
  • 5% Genomics and Pharmacogenomics in Anticancer Drug Development and Clinical Response
    Preț: 133176 lei
  • 5% COX-2 Blockade in Cancer Prevention and Therapy
    Preț: 105424 lei
  • 5% Cytokines in the Genesis and Treatment of Cancer
    Preț: 136353 lei

Preț: 173259 lei

Preț vechi: 182379 lei
-5% Nou

Puncte Express: 2599
Preț estimativ în valută:
33168€ • 36131$ • 27824£

Carte tipărită la comandă

Livrare economică 19 decembrie 24 - 02 ianuarie 25

 Adaugă în coș

Wish list
Gift list
Am citit!
Adaugă în listă
Preluare comenzi: 021 569.72.76

Specificații

ISBN-13: 9781493938988
ISBN-10: 1493938983
Pagini: 848
Ilustrații: IX, 836 p. 145 illus., 46 illus. in color.
Dimensiuni: 178 x 254 x 45 mm
Greutate: 1.44 kg
Ediția:Softcover reprint of the original 2nd ed. 2014
Editura: Springer
Colecția Humana
Seria Cancer Drug Discovery and Development

Locul publicării:New York, NY, United States

Cuprins

1. Molecular Targets.- 2. Preclinical Screening for New Anticancer Agents.- 3. Natural Product Screening.- 4. Defining the Starting Dose: Should it be mg/kg, mg/m2 or Fixed?.- 5. Phase 0 Trials in Oncology.- 6. Phase I Trials in Oncology - Design and Endpoints.- 7. Quantitative Analytical Methods: Development and Clinical Considerations.- 8. Validation and Control of Bioanalytical Methods.- 9. Anti-Cancer Clinical Pharmacology Overview.- 10. Pharmacokinetic Modeling.- 11. Pharmacometrics.- 12. Pharmacodynamic Modeling.- 13. Protein Binding.- 14. Metabolism (Non-CyP Enzymes).- 15. Pharmacogenomics and Cancer Therapy: Somatic and Germline Polymorphisms.- 16. Cytochrome P450.- 17. Polymorphisms in Genes of Drug Targets and Metabolism.- 18. DNA Repair: ERCC1, Nucleotide Excision Repair, and Platinum Resistance.- 19. Drug Interactions.- 20. ABC Transporters: Involvement in Multidrug Resistance and Drug Disposition.- 21. Solute carriers.- 22. High Throughput Platforms in Drug Metabolism and Transport Pharmacogenetics.- 23. Intrathecal Administration.- 24. Microdialysis.- 25. Regional Drug Delivery for Inoperable Pulmonary Malignancies.- 26. Blood-Brain-Barrier & CNS Malignancy.- 27. Radiation and Altering Clinical Pharmacology.- 28. Therapeutic Cancer Vaccines: An Emerging Approach to Cancer Treatment.- 29. Recombinant Immunotoxins.- 30. Monoclonal Antibodies.- 31. Clinical Pharmacology in Pediatrics.- 32. Clinical Pharmacology in the Elderly.- 33. Organ Dysfunction Trials:  Background, Historical Barriers, Progress in Overcoming Barriers and Suggestions for Future Trials.- 34. Drug Formulations: How this Affects Anticancer Drug Pharmacokinetics and Pharmacodynamics.- 35. Nanotechnology in Cancer.- 36. Imaging in Drug Development.- 37. Exposure-Response Relationship of Anticancer Agents: Application in Drug Development and Drug Label.- 38. The Role of Phase III Trials in Modern Drug Development.- 39. Clinical Trial Designs for Approval of New AnticancerAgents.- 40. Clinical Pharmacogenetics.

Recenzii

"...an invaluable overview of the experimental and clinical processes that lead to anticancer drugs, creating a single indispensable reference that covers all the steps from the identification of cancer-specific targets to phase III clinical trials." - Tumori

Notă biografică

Dr. Michelle Rudek received her BS in Pharmacy from the University of Pittsburgh and her dual Pharm.D., Ph.D. from Virginia Commonwealth University in a joint clinical pharmacology/oncology program with the National Cancer Institute.  Dr. Rudek joined Johns Hopkins University in 2001 and is currently an Associate Professor of Oncology and Director of the Analytical Pharmacology Core Laboratory.  Her research program is focused on clinical pharmacology with a focus on early phase drug development and special populations including AIDS malignancy and organ dysfunction.
Dr. Cindy H. Chau received her BS in Molecular, Cell, and Developmental Biology from UCLA and her Pharm.D. and Ph.D. (in Molecular Pharmacology and Toxicology) dual degrees from the University of Southern California School of Pharmacy as a National Institutes of Health (NIH) predoctoral fellow.  She was the recipient of the NIH National Research Service Award.  Dr. Chau completed a postdoctoral fellowship at the NIH, joining the National Cancer Institute in 2004 and is currently a research scientist within the Medical Oncology Branch, Center for Cancer Research.
Dr. William Douglas Figg received his B.S. (Hon) from Georgetown College, his B.S. in Pharmacy from Samford University and his Pharm.D. from Auburn University.  He completed his clinical pharmacy internship at the University of Alabama at Birmingham Hospital and his fellowship in drug development at the University of North Carolina-Chapel Hill.  Dr. Figg also received an M.B.A. degree from a combined program at Columbia University and London Business School.  He joined the Medical Oncology Branch, National Cancer Institute, National Institutes of Health in 1992. He has patented more than 80 new anticancer agents and four pharmacogenetic tests.
Dr. Howard McLeod is Fred Eshelman Distinguished Professor and Director, UNC Institute for Pharmacogenomics and Individualized Therapy,University of North Carolina, Chapel Hill.  Dr. McLeod holds appointments in the UNC Schools of Pharmacy and Medicine, the Carolina Center for Genome Sciences, and the Lineberger Comprehensive Cancer Center.  Dr McLeod is chair of the NHGRI eMERGE network external scientific panel and is a member of the FDA committee on Clinical Pharmacology.  He is a member of the NIH NHGRI Advisory Council.  Since 2002, Dr. McLeod has been vice chair for Pharmacogenomics for the NCI clinical trials cooperative group CALGB/ALLIANCE, overseeing the largest oncology pharmacogenomics portfolio in the world.

Textul de pe ultima copertă

There are many steps on the road from discovery of an anticancer drug to securing its final approval by the Food and Drug Administration. In this thoroughly updated and expanded second edition of the Handbook of Anticancer Pharmacokinetics and Pharmacodynamics, leading investigators synthesize an invaluable overview of the experimental and clinical processes of anticancer drug development, creating a single indispensable reference that covers all the steps from the identification of cancer-specific molecular targets to screening techniques and the development and validation of bioanalytical methods to clinical trial design and all phases of clinical trials. The authors have included new material on phase 0 trials in oncology, organ dysfunction trials, drug formulations and their impact on anticancer drug PK/PD including strategies to improve drug delivery, pharmacogenomics and cancer therapy, high throughput platforms in drug metabolism and transport pharmacogenetics, imaging in drug development and nanotechnology in cancer.
Authoritative and up-to-date, Handbook of Anticancer Pharmacokinetics and Pharmacodynamics, 2nd Edition provides in one comprehensive and highly practical volume a detailed step-by-step guide to the successful design and approval of anticancer drugs.
  • Road map to anticancer drug development from discovery to NDA submission
  • Discussion of molecular targets and preclinical screening
  • Development and validation of bioanalytical methods
  • Chapters on clinical trial design and phase 0, I, II, III clinical trials
  • Pharmacokinetics, pharmacodynamics, pharmacogenomics, and pharmacogenetics of anticancer agents
  • Review of the drug development process from both laboratory and clinical perspectives
  • New technological advances in imaging, high throughput platforms, and nanotechnology in anticancer drug development

Caracteristici

Provides a detailed step-by-step guide to the successful design and approval of anticancer drugs Features updated research from 1st Edition and new, additional chapters Explores a wide variety of issues, including clinical trial design, preclinical screening, and the development and validation of bioanalytic methods Includes supplementary material: sn.pub/extras